Darovasertib (IDE196)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Darovasertib (IDE196), covering 2026-02-17 to 2026-02-17. Get the full timeline:
Most recent: Clinical Trial Update: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma [Phase 2, Phase 3]